Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 511

1.

The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.

McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC.

BMC Pediatr. 2012 Jun 19;12:78. doi: 10.1186/1471-2431-12-78.

2.

Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.

Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, Hollis C, McCarthy S, Murray M, Planner C, Potts L, Sayal K, Taylor E.

Health Technol Assess. 2009 Oct;13(50):iii-iv, ix-xi, 1-120. doi: 10.3310/hta13490.

4.
5.

Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence.

McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC.

BMC Psychiatry. 2012 Dec 5;12:219. doi: 10.1186/1471-244X-12-219.

6.

Management of adult attention deficit hyperactivity disorder in UK primary care: a survey of general practitioners.

McCarthy S, Wilton L, Murray M, Hodgkins P, Asherson P, Wong IC.

Health Qual Life Outcomes. 2013 Feb 22;11:22. doi: 10.1186/1477-7525-11-22.

7.

Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany.

Lindemann C, Langner I, Kraut AA, Banaschewski T, Schad-Hansjosten T, Petermann U, Petermann F, Schreyer-Mehlhop I, Garbe E, Mikolajczyk RT.

J Child Adolesc Psychopharmacol. 2012 Aug;22(4):307-14. doi: 10.1089/cap.2011.0064. Epub 2012 Aug 2.

PMID:
22856384
8.

Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults.

McCarthy S, Asherson P, Coghill D, Hollis C, Murray M, Potts L, Sayal K, de Soysa R, Taylor E, Williams T, Wong IC.

Br J Psychiatry. 2009 Mar;194(3):273-7. doi: 10.1192/bjp.bp.107.045245.

9.

Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.

Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

J Manag Care Pharm. 2007 Sep;13(7):561-9.

10.
11.

Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.

Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A.

Ann Pharmacother. 2008 Jan;42(1):24-31. Epub 2007 Nov 27.

PMID:
18042808
12.

Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.

Mikolajczyk R, Horn J, Schmedt N, Langner I, Lindemann C, Garbe E.

JAMA Pediatr. 2015 Apr;169(4):391-5. doi: 10.1001/jamapediatrics.2014.3275.

PMID:
25686215
13.

Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed.

Preen DB, Calver J, Sanfilippo FM, Bulsara M, Holman CD.

Aust N Z J Public Health. 2007 Apr;31(2):120-6.

PMID:
17461001
14.
15.

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.

May DE, Kratochvil CJ.

Drugs. 2010;70(1):15-40. doi: 10.2165/11530540-000000000-00000.

PMID:
20030423
16.

Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015.

Renoux C, Shin JY, Dell'Aniello S, Fergusson E, Suissa S.

Br J Clin Pharmacol. 2016 Sep;82(3):858-68. doi: 10.1111/bcp.13000. Epub 2016 Jun 9.

17.

Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.

Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.

Curr Med Res Opin. 2014 Aug;30(8):1673-85. doi: 10.1185/03007995.2014.904772. Epub 2014 Apr 15. Review.

PMID:
24627974
18.

Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands.

Hodgkins P, Sasané R, Meijer WM.

Clin Ther. 2011 Feb;33(2):188-203. doi: 10.1016/j.clinthera.2011.03.001.

PMID:
21497704
19.

A nationwide study of attention-deficit/hyperactivity disorder drug use among adults in Iceland 2003-2012.

Geirs DP, Pottegård A, Halldórsson M, Zoëga H.

Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):417-22. doi: 10.1111/bcpt.12243. Epub 2014 May 6.

20.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

Supplemental Content

Support Center